Category: Aurobindo

Aurobindo Pharma (NS:) outperformed expectations in 4QFY24, with both sales and EBITDA showing significant year-on-year growth. Sales rose 17%, while EBITDA rose an impressive 68%, beating Goldman Sachs (NYSE:) expectations and those of the broader market. This strong performance was driven by strong growth in key geographic markets, both developed…